RCUS: Arcus Biosciences Inc

RCUS新闻

• 07:40 Reported Earlier, Arcus Biosciences Prices 14,285,715 Common Shares Public Offering At $17.50 Per Share, Targets $250M In Gross Proceeds
• 21:05 12 Health Care Stocks Moving In Wednesday's After-Market Session
• 18:54 Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50
• 14:00 Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
• 13:10 Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41
• 13:00 Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
• 12:35 Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS)
• 22:23 Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
• 13:45 Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal
• 13:00 Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
• 12:38 Arcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending
• 14:30 William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating
• 12:52 JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
• 12:52 摩根大通开始覆盖 Arcus Biosciences，给予增持评级，并公布 41 美元目标价
• 12:25 Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target
• 12:25 Wedbush重申对Arcus Biosciences的“跑赢大盘”评级，并维持43美元目标价